Navigation Links
Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
Date:10/30/2008

itive and the announcement of top-line results is expected in the second half of 2009.

Clinical Trial Results to Date

In the BHT-3021 phase I/II clinical trial, 44 patients have thus far been randomized to four different dose cohorts of BHT-3021 (0.3 mg, 1 mg, 3 mg, or 6 mg). BHT-3021 has demonstrated safety and tolerability, with no increase in adverse events relative to placebo. Preliminary data from the 1 mg dose cohort indicate that treatment with BHT-3021 may cause beta cell preservation as well as the induction of immune tolerance to pancreatic autoantigens. Clinical Trial Criteria

Key inclusion criteria for this trial include: a diagnosis of type 1a diabetes mellitus based on ADA criteria, ≤5 years since T1D was diagnosed, ≥ 18 years of age, ≤ 40 years of age at the time of diagnosis of Type 1 diabetes, detectable fasting C-peptide level, C-peptide increase during screening mixed meal tolerance test, and presence of antibodies to at least one beta cell antigen (insulin, GAD-65, or IA-2). ClinicalTrials.gov Identifier: NCT00453375.


'/>"/>

Contact: Leslie Schwartz
lschwartz@jdrf.org
212-479-7553
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
2. Michael J. Fox Foundation PD Therapeutics Conference
3. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
4. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
5. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
6. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
7. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
8. Gender, coupled with diabetes, affects vascular disease development
9. Breakthrough research identifies how cells from pigs may cure diabetes
10. Botched production of insulin molecule may lead to diabetes
11. Joslin researchers uncover potential role of leptin in diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... University of Alberta researchers discover that animals zig when ... told them. , In studying the spatial memory of ... to discover the birds contradicting prior research that showed ... reveal a different pattern. Previously, only animals that had ...
... study suggests that a suspect gene may increase susceptibility ... processing negative emotion. People with the depression-linked gene variant ... mood-regulating circuit. How well the circuit was connected accounted ... at the National Institute of Health's (NIH) National Institute ...
... billion neurons, and each has hundreds of connections with ... essential to understanding brain function, and the task is ... approach to mapping neuron connectivity published in PLoS Computational ... of Neuroscience at the University of Minnesota, the task ...
Cached Biology News:Chickadees can help humans get their bearings 2Depression gene may weaken mood-regulating circuit 2Depression gene may weaken mood-regulating circuit 3
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
(Date:10/25/2014)... A new way to produce engineered ... current skin grafting technologies, it also speeds up the ... outlined in the October issue of STEM CELLS Translational ... injuries that result from severe burns and chronic wounds. ... regenerative elements. These wounds heal by contraction, with epithelization ...
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... and BOSTON , Oct. 22, ... a leading global specialty pharmaceutical company, and Rhythm, a ... an exclusive option to acquire Rhythm,s wholly owned subsidiary, ... peptide ghrelin agonist, for the treatment of diabetic gastroparesis ... has completed a successful Phase 2 trial of relamorelin ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... dollars, QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - ... a global biopharmaceutical company focused on,endocrine therapy and ... agreement to sell to Cowen Healthcare Royalty Partners, ... of Cetrotide(R) covered by,its license agreement with Merck ...
... Pasteur and Chumakov Institute Russian Academy Medical Sciences, ... ... National "Project Health", PARIS, November 12 ... Russia has,chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for ...
... Standard & Poor,s will make the,following changes to the S&P 500 and S&P ... GGP) will be removed from the S&P 500 ... today,s close of trading General Growth Properties had a ... in the index., -- S&P MidCap 400 constituent Cephalon Inc. ...
Cached Biology Technology:AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 2Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 5Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 6Standard & Poor's Announces Changes to U.S. Indices 2Standard & Poor's Announces Changes to U.S. Indices 3